Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer

Journal of the National Cancer Institute

Volumn 105, Issue 1, 2013, Pages 69-73

  Kohaar, Indu ^a   Porter Gill, Patricia ^a   Lenz, Petra ^c   Fu, Yi Ping ^a   Mumy, Adam ^a   Tang, Wei ^a   Apolo, Andrea B ^b   Rothman, Nathaniel ^a   Baris, Dalsu ^a   Schned, Alan R ^d   Ylaya, Kris ^b   Schwenn, Molly ^e   Johnson, Alison ^f   Jones, Michael ^g   Kida, Masatoshi ^h   Silverman, Debra T ^a   Hewitt, Stephen M ^b   Moore, Lee E ^a   Prokunina Olsson, Ludmila ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Center for Cancer Research   (United States)

^c SAIC FREDERICK INC   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e Maine Cancer Registry   (United States)

^f Vermont Cancer Registry   (United States)

^g MAINE MEDICAL CENTER   (United States)

^h UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; PROSTATE STEM CELL ANTIBODY; PROSTATE STEM CELL ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; DISEASE MARKER; DISEASE SEVERITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LINEAR MODELS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84871942874     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs458     Document Type: Article

References (40)

1. Chung CC, Chanock SJ. Current status of genome-wide association studies in cancer. Hum Genet. 2011;130(1):59-78.
2. Rothman N, Garcia-Closas M, Chatterjee N, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet. 2010;42(11):978-984.
3. Wu X, Ye Y, Kiemeney LA, et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet. 2009;41(9):991-995.
4. Amara N, Palapattu GS, Schrage M, et al. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res. 2001;61(12):4660-4665. (Pubitemid 32691871)
5. Barbisan F, Mazzucchelli R, Santinelli A, et al. Expression of prostate stem cell antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. Histopathology. 2010;57(4):572-579.
6. Cheng L, Reiter RE, Jin Y, et al. Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens. J Urol. 2003;169(6): 2094-2100. (Pubitemid 36576725)
7. Elsamman EM, Fukumori T, Tanimoto S, et al. The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis. BJU Int. 2006;98(3):668-673. (Pubitemid 44185896)
8. Geiger KD, Hendruschk S, Rieber EP, Morgenroth A, Weigle B, Juratli T, et al. The prostate stem cell antigen represents a novel glioma-associated antigen. Oncol Rep. 2011;26(1):13-21.
9. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000;19(10):1288-1296. (Pubitemid 30160621)
10. Kawaguchi T SM, Tojo T, Yamato I, Nomi T, Hotta K, Hamada K, Suzaki Y, Sugiura S, Kushibe K, Nakajima Y, Taniguchi S. Clinical significance of prostate stem cell antigen expression in non-small cell lung cancer. Jpn J Clin Oncol. 2010;40(4):319-326.
11. Liu WK JX, Zhang ZX. Expression of PSCA, PIWIL1, and TBX2 in endometrial adenocarcinoma. Onkologie. 2010;33(5):241-245.
12. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA. 1998;95(4):1735-1740. (Pubitemid 28103463)
13. Saeki N, Gu J, Yoshida T, Wu X. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res 2010;16(14):3533-3538.
14. Tanikawa C, Urabe Y, Matsuo K, et al. A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. Nat Genet. 2012;44(4): 430-434.
15. Antonarakis ES, Carducci MA, Eisenberger MA, et al. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemother Pharmacol. 2012;69(3):763-771.
16. Morris MJ, Eisenberger MA, Pili R, Denmeade SR, Rathkopf D, Slovin SF, et al. A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Ann Oncol. 2012;23(10):2714-2719.
17. Raff AB, Gray A, Kast WM. Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett. 2009;277(2):126-132.
18. Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002;62(9):2546-2553. (Pubitemid 34462733)
19. Wente MN, Jain A, Kono E, et al. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas. 2005;31(2): 119-125. (Pubitemid 41077139)
20. Wolpin BM, O'Reilly EM, Ko Y, et al. Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol. 2011;29(Suppl):abstrct 4031.
21. Fu YP, Kohaar I, Rothman N, Earl J, Figueroa JD, Ye Y, et al. Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. Proc Natl Acad Sci USA. 2012;109(13):4974-49799.
22. Burbano RR, Assumpcao PP, Leal MF, et al. C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil. Anticancer Res. 2006;26(4B):2909-2914.
23. Reiter RE, Sato I, Thomas G, et al. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer. 2000;27(1):95-103.
24. Zaharieva B, Simon R, Ruiz C, et al. Highthroughput tissue microarray analysis of CMYC amplificationin urinary bladder cancer. Int J Cancer. 2005;117(6):952-956. (Pubitemid 41688569)
25. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds.) : TNM staging system for bladder cancer. In AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010:497-505.
26. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22(12):1435-1448. (Pubitemid 28550639)
27. Gu Z, Yamashiro J, Kono E, Reiter RE. Antiprostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res. 2005;65(20):9495-9500. (Pubitemid 41508019)
28. Katz BZ, Eshel R, Sagi-Assif O, Witz IP. An association between high Ly-6A/E expression on tumor cells and a highly malignant phenotype. Int J Cancer. 1994;59(5):684-691. (Pubitemid 24358593)
29. Marra E, Uva P, Viti V, et al. Growth delay of human bladder cancer cells by prostate stem cell antigen downregulation is associated with activation of immune signaling pathways. BMC Cancer. 2010;10:129.
30. Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA. 2001;98(5):2658-2663. (Pubitemid 32209538)
31. Zhao Z, Ma W, Zeng G, Qi D, Ou L, Liang Y. Small interference RNA-mediated silencing of prostate stem cell antigen attenuates growth, reduces migration and invasion of human prostate cancer PC-3M cells. Urol Oncol. 2004. Article in press; http://dx. doi. org/10. 1016/j. urolonc. 2011. 02. 004.
32. Ryu B, Jones J, Blades NJ, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res. 2002;62(3):819-826. (Pubitemid 34126959)
33. Golka K, Selinski S, Lehmann ML, et al. Genetic variants in urinary bladder cancer: collective power of the "wimp SNPs. " Arch Toxicol. 2011;85(6):539-554.
34. Lu Y, Chen J, Ding Y, et al. Genetic variation of PSCA gene is associated with the risk of both diffuse-and intestinal-type gastric cancer in a Chinese population. Int J Cancer. 2010;127(9):2183-2189.
35. Matsuo K, Tajima K, Suzuki T, et al. Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese. Int J Cancer. 2009;125(8):1961-1964.
36. Qiao L, Feng Y. Genetic variations of prostate stem cell antigen (PSCA) contribute to the risk of gastric cancer for Eastern Asians: a meta-analysis based on 16792 individuals. Gene. 2012;493(1):83-91.
37. Sakamoto H, Yoshimura K, Saeki N, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet. 2008;40(6):730-740. (Pubitemid 351748870)
38. Shi D, Wang S, Gu D, et al. The PSCA polymorphisms derived from genome-wide association study are associated with risk of gastric cancer: a meta-analysis. J Cancer Res Clin Oncol. 2012;138(8):1339-1345.
39. Wang S, Tang J, Wang M, Yuan L, Zhang Z. Genetic variation in PSCA and bladder cancer susceptibility in a Chinese population. Carcinogenesis. 2010;31(4):621-624.
40. Wang T, Zhang L, Li H, Wang B, Chen K. Prostate stem cell antigen polymorphisms and susceptibility to gastric cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(5):843-850.